Major Mergers, Acquisitions, and Collaborations in the Pharmaceutical Industry in 2020!

1. Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

2. AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development

3. AstraZeneca divestment of Movantik to RedHill Biopharma completed

4. AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

5. AstraZeneca: Atacand to be divested to Cheplapharm in more than 70 countries

6. AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialize new antibody-drug conjugate

7. AstraZeneca collaborates with ArcherDX to use personalized cancer assays to detect minimal residual disease in lung cancer trials

8. AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

9. Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

10. AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan

11.Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) 

12. Gilead Sciences Completes Acquisition of Immunomedics, Inc.

13. Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

14. Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

15. Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

16. Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

17. Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies

18. Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

19. Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

20. Gilead Completes Acquisition of Forty Seven, Inc.

21. Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

22. Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

23. Selvita to acquire Fidelta from Galapagos

24. OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

25. Galapagos and Ryvu announce research collaboration

26. Fibrocor and Galapagos sign expanded collaboration in fibrosis

27. Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products

28. Sanofi completes Principia Biopharma Inc. acquisition

29. Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

30. Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

31. Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.

32. Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19

33. Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus

34. Merck to Acquire VelosBio

35. Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

36. Merck Animal Health Completes Acquisition of IdentiGEN

37. Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

38. Merck Completes Acquisition of ArQule

39. Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

40. Merck Animal Health Completes Acquisition of Quantified Ag®

41. Merck Completes Acquisition of Themis

42. Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801

43.  Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials

44. Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

45. Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19

46. Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

47. Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use

48. Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize relugolix in Oncology and Women's Health

49. Pfizer and BioNTech Receive Authorization in the European Union and US for COVID-19 Vaccine

50. Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

51. Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

52. Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

53. IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs

54. Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

55. Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

56. Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

57. Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

58. Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

59. Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines

60. Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

61. Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals

62. Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines

63. Bayer sells a facility at its Wuppertal site to WuXi Biologics

64. Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors

65. Bayer and Blackford Analysis to Collaborate on Integration of AI Solutions in Medical Imaging Workflow

66. Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

67. Bayer Acquires Majority Stake in Care/of

68. Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy

69. Leaps by Bayer leads USD 17 million Series B financing in biotech company Azitra

70. Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™

71. Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases

72. Bayer completes the acquisition of UK-based biotech company KaNDy Therapeutics Ltd.

73. Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics

74. Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas

75. Bayer completes the sale of its Animal Health business unit to Elanco

76. Bayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™

77. Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments

78. Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications

79. Bayer and Azitra partner to harness the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin

80. Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery

81. Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome

82. Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.

83. Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

84. Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

85. Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise

86. Bristol Myers Squibb Completes Acquisition of Forbius

87. Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics For Oncology

88. BioMotiv and Bristol-Myers Squibb announce the Launch of Anteros Pharmaceuticals

89. Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

90. Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities

91. Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

92. Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

93. Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

94. Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

95. Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

96. Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

97. Lilly Announces Agreement to Acquire Prevail Therapeutics

98. Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

99. Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

100. Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

101. Lilly Announces Agreement to Acquire Disarm Therapeutics

102. Lilly and Dexcom team up on a new program to help improve diabetes management

103. AGC Biologics Expands Partnership with Novavax

104. Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

105. Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

106. Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

107. AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

108. Lilly Completes Acquisition of Dermira

109. ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio

110. ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration

111. ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

112. Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

113. MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

114. Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic

115. Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries

116. GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

117. GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

118. GSK and CureVac announce strategic mRNA technology collaboration

119. IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology

120. GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

121. Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with a pandemic adjuvant system

122. CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus

123. Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

124. Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

125. Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

126. Chiesi Group and Apotex Inc. finalize an agreement for the acquisition of Ferriprox® (deferiprone)

127. Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

128. Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

129. Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

130. Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

131. Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

132. Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

133. G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico

134. Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

135. Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide

136. Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

137. Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

138. AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

139. Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business

140. AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

141. AbbVie and Genmab Announce Broad Oncology Collaboration

142. AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

143. AbbVie Completes Transformative Acquisition of Allergan

144. ProThera Biologics and Takeda Enter Global Licensing Agreement

145. Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

146. Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

147. Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

148. Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology

149. Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

150. Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication

151. Eisai and Wren Therapeutics enter into research collaboration agreement for drug discovery for synucleinopathies

152. Eisai and JD Health establish a joint venture company in china to implement a health service platform

153. Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

154. Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea & China

155. Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

156. Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab

157. Daiichi Sankyo Announces Establishment of DAIICHI SANKYO VIETNAM COMPANY LIMITED

158. Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

159. The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)

160. Daiichi Sankyo, Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open Innovation Research on Gene Therapy to Restore Vision

161. Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology

162. Daiichi Sankyo and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan

163. Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

164. UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA[®] (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

165. UCB acquires Engage Therapeutics: Staccato[®] Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy

166. UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients

167. Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

168. Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

169. Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States

170. PharmaMar and Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

171. KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus

172. Astellas Completes Acquisition of iota Biosciences

173. Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

174. Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research

175. Astellas Completes Acquisition of Audentes Therapeutics

176. Lexicon Pharmaceuticals Enters Data Collaboration with AC Bioscience

177. Lexicon Pharmaceuticals Completes the Sale of Xermelo to TerSera Therapeutics

178. Lexicon Pharmaceuticals Enters Into Agreement with Tersera Therapeutics for the Sale of Xermelo

179. CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

180. CSL Behring to Acquire Biotech Company Vitaeris

181. Thermo Fisher Scientific and CSL Enter Strategic Partnership

182. CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

183. Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

184. Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson

185. Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

186. Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

187. Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company

188. Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

189. Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

190. Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.

191. Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

192. Shionogi and Nagasaki University Entered into Strategic Research Collaboration for Antimalarial Drugs with The Kitasato Institute

193. Shionogi and HanaVax Enter into a License Agreement for Streptcoccus Pneumoniae Vaccine Candidate

194. Shionogi Pharma to acquire Nagase Medicals as a wholly owned subsidiary

195. Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770, the Drug Candidates for the Treatment of Brain Disorders Marked by Cognitive and Memory Deficits

196. La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

197. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

198. Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

199. Grifols and Shanghai RAAS close their strategic alliance in China

200. ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China      

201. Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

202. Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics

203. Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

204. Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19

205. Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in-Class ‘Gene-Silencing’ RNAi Therapeutic

206. Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells

207. Sangamo Announces Closing of Biogen Collaboration Agreement

208. Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation

209. Collegium Announces Closing of the Nucynta Franchise Acquisition

210. MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule

211. MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

212. Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases

213. Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing

214. CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

215. Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

216. Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

217. Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System

218. CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System

219. CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis

220. Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis

221. EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

222. 23andMe signs a strategic agreement with Almirall

223. Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA™ for Middle East & North Africa regions

224. Sun Pharma and SPARC enter into a worldwide license agreement for SCD 044

225. Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in India

226. Chugai and DeNA Jointly Launch “Ring Again,” a Rheumatoid Arthritis Disease Awareness Project

227. Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk, Argenx, & Eli Lilly and Company

228. Chugai Announces Global Licensing Agreement with Verastem Oncology for RAF/MEK Inhibitor CKI27

229. Chugai Files Patent Infringement Lawsuit against Fresenius Kabi in the U.S.

230. Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery Support System

231. Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

232. Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan

233. InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

234. Axcelead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development

235. Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio®

236. Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

237. MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

238. Ferring Pharmaceuticals and Kyowa Kirin Announce Termination the License Agreement and the Supply and Co-Promotion Agreement of Pharmaceutical Products of Desmopressin

239. Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry

240. Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs

241. Syneos Health Acquires Illingworth Research Group, a Leading Provider of Clinical Research Home Health Services

242. Syneos Health Completes Acquisition of Synteract

243. VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

244. Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

245. Idorsia Selects Syneos Health as Commercialization Partner to Launch Daridorexant in the United States

246. Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline

247. Otsuka America Pharmaceutical, Inc., Purchases the Assets of Proteus Digital Health, Inc.

248. Otsuka Pharmaceutical Development & Commercialization, Inc. Launches NephU, an Online Healthcare Community Dedicated to Kidney Health

249. Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals

250. INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea

251. IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea

252. Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

253. Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China

254. Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate

Sonali Pandhe Ph.D. is an AMAG Pharmaceutical's employee. All the views and perspectives are fully independent. They do not represent any views of AMAG Pharmaceuticals or any other company. The information compiled in this post is publicly available. Thank you!